SCHEDULE: Vanguard Group Divests Fate Therapeutics Stake
Beneficial Ownership Update
The Vanguard Group reports zero beneficial ownership in Fate Therapeutics Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 6 to Schedule 13G for Fate Therapeutics Inc. Common Stock.
- The filing indicates that The Vanguard Group now holds 0 shares, representing 0% of the class of securities.
- This change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral for Fate Therapeutics Inc. as it primarily reflects an internal organizational change within The Vanguard Group's reporting structure, not a change in investment thesis regarding the issuer.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that this filing reflects an administrative change within The Vanguard Group's reporting structure rather than a strategic investment decision related to Fate Therapeutics Inc. This type of internal realignment is common among large asset managers to comply with regulatory guidance on beneficial ownership reporting.
Stakeholder Impact
- Shareholders of Fate Therapeutics Inc. may observe a change in institutional ownership data, but this specific filing does not indicate a change in investment sentiment from Vanguard's underlying funds, which will now report separately.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | Internal realignment of The Vanguard Group, Inc. leading to disaggregated reporting by subsidiaries. |
| 03/13/2026 | Date of event which requires the filing of this statement. |
| 03/26/2026 | Date of signing and filing of the Schedule 13G Amendment No. 6. |
Keywords
Fate Therapeutics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, Investment Adviser, FTTE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.